Dedifferentiated Liposarcoma With Myofibroblastic Differentiation
Authors:
- Grace Y. WangGWGrace Y. Wang
- David R. LucasDLDavid R. Lucas
- 1 October 2018
- journal article
- research article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (10) , 1159-1163
Abstract
Context.—: Liposarcoma is divided into myxoid, pleomorphic, well-differentiated, and dedifferentiated subtypes. Dedifferentiated liposarcoma displays the greatest histomorphologic diversity, including a subset with myofibroblastic differentiation that shares similarities with a spectrum of reactive, benign, and malignant soft tissue lesions. Misdiagnosis may lead to deleterious consequences, as dedifferentiated liposarcoma differs significantly in its prognosis and treatment from its mimics. Objective.—: To review the clinicopathologic, immunohistochemical, and molecular features of the myofibroblastic variant of dedifferentiated liposarcoma as well as the key distinguishing features from its mimics. Data Sources.—: Review of pertinent literature on major features and current understanding of dedifferentiated liposarcoma with myofibroblastic differentiation. Conclusions.—: The myofibroblastic variant of dedifferentiated liposarcoma is an uncommon and underrecognized sarcoma with several important differential diagnoses, and likely represents the major subset of aggressive retroperitoneal tumors that may have been misdiagnosed as desmoid-type fibromatosis, inflammatory myofibroblastic tumor, or another type of sarcoma in the past.Keywords
This publication has 32 references indexed in Scilit:
- Tumours composed of fat are no longer a simple diagnosis: an overview of fatty tumours with a spindle cell componentJournal of Clinical Pathology, 2018
- Clinical and Molecular Spectrum of LiposarcomaJournal of Clinical Oncology, 2018
- Recent advances in the management of liposarcomaF1000Research, 2016
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor PalbociclibJAMA Oncology, 2016
- Dedifferentiated LiposarcomaAdvances in Anatomic Pathology, 2016
- Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With AdvancedCDK4-Amplified Well-Differentiated or Dedifferentiated LiposarcomaJournal of Clinical Oncology, 2013
- Dedifferentiated Liposarcoma With Inflammatory Myofibroblastic Tumor-like FeaturesAmerican Journal of Surgical Pathology, 2010
- Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiationLaboratory Investigation, 2005
- Retroperitoneal Liposarcoma With Combined Well-Differentiated and Myxoid Malignant Fibrous Histiocytoma–Like Myxoid AreasAmerican Journal of Surgical Pathology, 1999
- Liposarcoma A study of 55 cases with a reassessment of its classificationAmerican Journal of Surgical Pathology, 1979